Stockscreener 앱 받기
4.58
0.33%
0.015
시간 외 거래:
4.58
전일 마감가:
$4.565
열려 있는:
$4.53
하루 거래량:
1.90M
Relative Volume:
0.60
시가총액:
$394.85M
수익:
$7.62M
순이익/손실:
$-271.60M
주가수익비율:
-1.3079
EPS:
-3.5018
순현금흐름:
$-271.54M
1주 성능:
+2.23%
1개월 성능:
-60.75%
6개월 성능:
-74.56%
1년 성능:
-61.45%
1일 변동 폭
$4.485
$4.69
1주일 범위
$4.325
$4.915
52주 변동 폭
$3.95
$19.11
Eyepoint Inc Stock (EYPT) Company Profile
명칭
Eyepoint Inc
전화
617-926-5000
주소
480 PLEASANT STREET, WATERTOWN, MA
Compare EYPT vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EYPT
Eyepoint Inc
|
4.58 | 465.55M | 7.62M | -271.60M | -271.54M | -3.5018 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Eyepoint Inc Stock (EYPT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-17 | 개시 | RBC Capital Mkts | Outperform |
| 2025-01-07 | 개시 | Citigroup | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-08-28 | 개시 | Jefferies | Buy |
| 2024-01-22 | 개시 | JP Morgan | Overweight |
| 2023-11-02 | 개시 | Mizuho | Buy |
| 2023-04-21 | 개시 | Robert W. Baird | Outperform |
| 2022-07-07 | 개시 | Chardan Capital Markets | Buy |
| 2021-03-01 | 개시 | Cowen | Outperform |
| 2021-01-28 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-04-06 | 다운그레이드 | B. Riley FBR | Buy → Neutral |
| 2019-11-04 | 재개 | Laidlaw | Buy |
| 2019-09-12 | 개시 | Guggenheim | Buy |
모두보기
Eyepoint Inc 주식(EYPT)의 최신 뉴스
EyePoint's stock plunges 66% after failed Phase 3 trial for wet AMD treatment. - Pluang
Investigation Alert: EyePoint, Inc. (EYPT) Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP - PR Newswire
EyePoint, Inc. (NASDAQ: EYPT) Alert: Investors Encouraged to Contact KTMC Law Firm - GlobeNewswire Inc.
EyePoint (EYPT) Stock Sees Fair Value Cut After Split Analyst Revisions On LUGANO - Yahoo Finance
EyePoint, Inc (NASDAQ: EYPT) Share Price, EYPT Stock News, EYPT Share Price & Updates - kalkine.ca
EyePoint faces securities fraud probe after tri... - Pluang
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc.EYPT - PR Newswire
EYPT INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving EyePoint Pharmaceuticals - globenewswire.com
EYEPOINT STOCKHOLDER ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
EyePoint stock drops as TD Cowen downgrades (EYPT:NASDAQ) - Seeking Alpha
TD Cowen Downgrades EyePoint Pharmaceuticals to Hold From Buy, Adjusts PT to $4 From $20 - marketscreener.com
EyePoint Announces Upcoming Investor Conference and Retina Society Presentations - Quiver Quantitative
Four retinal-disease studies are slated for Los Angeles. EyePoint will present them. - Stock Titan
TD Cowen downgrades EyePoint stock to Hold on trial concerns By Investing.com - Investing.com Canada
TD Cowen downgrades EyePoint stock to Hold on trial concerns - Investing.com
EYPT SHAREHOLDER ALERT: EyePoint Pharmaceuticals Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations - Business Wire
EYPT Investors Have Opportunity to Join EyePoint, Inc. Fraud Investigation with SBS Law - financialcontent.com
Eyepoint Pharmaceuticals Inc (EYPT) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Eyepoint Pharmaceuticals Inc (EYPT) Key Financial Ratios – Valuation, Profitability & More - valueresearchonline.com
EyePoint After LUGANO: Primary Endpoint Miss, Asymmetric Risk-Reward (NASDAQ:EYPT) - Seeking Alpha
EYEPOINT PHARMACEUTICALS INVESTOR ALERT: Kirby McInerney - GlobeNewswire
EyePoint (EYPT) CFO moves 139K shares into family and annuity trusts - Stock Titan
EyePoint's drug for age-related eye disease fails late-stage trial, shares tank 70% - The Economic Times
Taxes of EyePoint, Inc. – HAM:PV3B - TradingView
EYPT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into EyePoint Pharmaceuticals (EYPT) - Business Wire
EYPT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving EyePoint Pharmaceuticals - PR Newswire
OCUL, FDMT Stock Clock Best Day In Weeks After EyePoint’s Trial Setback — Here’s Why - Stocktwits
EyePoint's Wet AMD Drug Duravyu Fails Key Late-Stage Trial - Medical Dialogues
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Shares Gap UpHere's Why - MarketBeat
EyePoint: Sell-Off As Duravyu Fails Head-To-Head Study Vs Eylea May Be Overblown (NASDAQ:EYPT) - Seeking Alpha
EyePoint: Still A Sell After Phase 3 Crash (NASDAQ:EYPT) - Seeking Alpha
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Downgraded by Royal Bank Of Canada to "Hold" - MarketBeat
These Analysts Slash Their Forecasts On EyePoint - Sahm
EyePoint director Karen L. Zaderej buys $52,258 in stock - Investing.com South Africa
EyePoint director Karen Zaderej reports purchase of 10,600 shares worth $52,258 - Bitget
EyePoint (EYPT) Insider Karen Zaderej Buys 10,600 Shares, Signaling Confidence - GuruFocus
EyePoint Director Karen Zaderej Acquires 10,600 Shares in Open-Market Transaction - Kalkine Media
EyePoint director Karen L. Zaderej buys $52,258 in stock By Investing.com - Investing.com Australia
EyePoint (EYPT) director adds to stake in open‑market buy - Stock Titan
EyePoint IncInterim Phase 3 Data Shows Con - Moomoo
EYPT Maintains Buy Rating by Citigroup -- Price Target Lowered to $17.00 - GuruFocus
EyePoint Inc. (EYPT) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
EYPT Stock Crashes On Duravyu Data But Catalysts Loom - StocksToTrade
Traders Buy Large Volume of Call Options on Eyepoint Pharmaceuticals (NASDAQ:EYPT) - MarketBeat
EYPT Looks 1359.7% Overvalued on GF Value™ - GuruFocus
Citigroup Issues Pessimistic Forecast for Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price - MarketBeat
EYEPOINT INC : CITIGROUP CUTS TARGET PRICE TO $17 FROM $35 - Moomoo
EyePoint Faces Regulatory Uncertainty After Lugano Trial Miss, RBC Capital Markets Says - marketscreener.com
EyePoint, Inc. (EYPT) Discusses LUGANO Top Line Data From Phase III Wet AMD Trial for DURAVYUSlideshow - Seeking Alpha
EyePoint’s Duravyu falls short to Eylea in Phase III trial - Yahoo Finance
EYPT Stock Plunges 67% After Duravyu Misses Phase III Eye Disease Goal - TradingView
Eyepoint Inc (EYPT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.86%
0.31%
자본화:
|
볼륨(24시간):